Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade

British Journal of Clinical Pharmacology

Volumn 72, Issue 3, 2011, Pages 415-433

  Kleijn, Huub J ^a   Zollinger, Daniel P ^a   van den Heuvel, Michiel W ^a   Kerbusch, Thomas ^a  

^a NV ORGANON   (Netherlands)

Author keywords

Elderly; Nonlinear mixed effects model; Paediatric; Population pharmacokinetics and pharmacodynamics; Renal function

Indexed keywords

PROPOFOL; ROCURONIUM; SEVOFLURANE; SUGAMMADEX;

ACCURACY; AGE; ARTICLE; BODY WEIGHT; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EXTERNAL VALIDITY; HUMAN; INTERNAL VALIDITY; KIDNEY FUNCTION; NEUROMUSCULAR BLOCKING; NONLINEAR SYSTEM; PHARMACODYNAMICS; POPULATION MODEL; PRIORITY JOURNAL; RACE; SIMULATION; STATISTICAL PARAMETERS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANDROSTANOLS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; FEMALE; GAMMA-CYCLODEXTRINS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; MODELS, NEUROLOGICAL; MUSCLE RELAXATION; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR NONDEPOLARIZING AGENTS; YOUNG ADULT;

EID: 79961156319     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04000.x     Document Type: Article

References (44)

1. Bevan DR. Monitoring and reversal of neuromuscular block. Am J Health Syst Pharm 1999; 56: (Suppl. 1): S10-13.
2. Srivastava A, Hunter JM. Reversal of neuromuscular block. Br J Anaesth 2009; 103: 115-29.
3. Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharmacology of sugammadex. J Crit Care 2009; 24: 29-35.
4. Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103: 695-703.
5. Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, Viby-Mogensen J. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006; 104: 667-74.
6. Sparr HJ, Vermeyen KM, Beaufort AM, Rietbergen H, Proost JH, Saldien V, Velik-Salchner C, Wierda JM. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology 2007; 106: 935-43.
7. de Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology 2007; 107: 239-44.
8. Schering-Plough. A Bridging Trial Comparing Org 25969 at Reappearance of T2 in Japanese and Caucasian Subjects. Part A: Japanese Subjects (19.4.208A) (P05956)(COMPLETED). Date last updated: October 2, 2009. Available at (last accessed 20 July 2010).
9. Pühringer FK, Gordon M, Demeyer I, Sparr HJ, Ingimarsson J, Klarin B, van Duijnhoven W, Heeringa M. Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. Br J Anaesth 2010; 105: 610-9.
10. Staals LM, Snoeck MM, Driessen JJ, van Hamersvelt HW, Flockton EA, van den Heuvel MW, Hunter JM. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br J Anaesth 2010; 104: 31-9.
11. McDonagh DL, Benedict PE, Kovac AL, Drover DR, Brister NW, Morte JB, Monk TG. Efficacy, safety, and pharmacokinetics of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in elderly patients. Anesthesiology 2011; 114: 318-29.
12. Plaud B, Meretoja O, Hofmockel R, Raft J, Stoddart PA, van Kuijk JH, Hermens Y, Mirakhur RK. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009; 110: 284-94.
13. Suy K, Morias K, Cammu G, Hans P, van Duijnhoven WG, Heeringa M, Demeyer I. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007; 106: 283-8.
14. Vanacker BF, Vermeyen KM, Struys MM, Rietbergen H, Vandermeersch E, Saldien V, Kalmar AF, Prins ME. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg 2007; 104: 563-8.
15. Blobner M, Eriksson LI, Scholz J, Motsch J, Della Rocca G, Prins ME. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol 2010; 27: 874-81.
16. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology 2008; 109: 816-24.
17. Lee C, Jahr JS, Candiotti KA, Warriner B, Zornow MH, Naguib M. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology 2009; 110: 1020-5.
18. Peeters P, Passier P, Smeets J, Zwiers A, de Zwart M, van Marle S. Sugammadex is cleared rapidly and primarily in an unchanged form via renal excretion. Clinical. Pharmacol Ther 2009; 85: (Suppl. 1): S83. (Abstract PIII-50).
19. Peeters PA, van den Heuvel MW, van Heumen E, Passier PC, Smeets JM, van Iersel T, Zwiers A. Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96mg/kg) in healthy adult subjects: a randomized, double-blind, crossover, placebo-controlled, single-centre study. Clin Drug Investig 2010; 30: 867-74.
20. Ploeger BA, Smeets J, Strougo A, Drenth HJ, Ruigt G, Houwing N, Danhof M. Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex. Anesthesiology 2009; 110: 95-105.
21. Bock M, Klippel K, Nitsche B, Bach A, Martin E, Motsch J. Rocuronium potency and recovery characteristics during steady-state desflurane, sevoflurane, isoflurane or propofol anaesthesia. Br J Anaesth 2000; 84: 43-7.
22. Lowry DW, Mirakhur RK, McCarthy GJ, Carroll MT, McCourt KC. Neuromuscular effects of rocuronium during sevoflurane, isoflurane, and intravenous anesthesia. Anesth Analg 1998; 87: 936-40.
23. Woloszczuk-Gebicka B, Wyska E, Grabowski T, Swierczewska A, Sawicka R. Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. Paediatr Anaesth 2006; 16: 761-8.
24. Woloszczuk-Gebicka B, Wyska E, Grabowski T. Sevoflurane increases fade of neuromuscular response to TOF stimulation following rocuronium administration in children. A PK/PD analysis. Paediatr Anaesth 2007; 17: 637-46.
25. de Zwart MAH, ten Bruggencate-Broeders J, van Hal HJM, Megens HJJJ, Frasa WLH. Determination of sugammadex in human plasma, urine, and dialysate using a high-performance liquid chromatography/tandem mass spectrometry assay. J Chromatogr B 2011; 879: 1573-86.
26. Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J. 8th International Neuromuscular Meeting. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand 2007; 51: 789-808.
27. Claudius C, Skovgaard LT, Viby-Mogensen J. Acceleromyography and mechanomyography for establishing potency of neuromuscular blocking agents: a randomized-controlled trial. Acta Anaesthesiol Scand 2009; 53: 449-54.
28. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit-A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79: 241-57.
29. Wählby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 2001; 28: 231-52.
30. Wählby U, Bouw MR, Jonsson EN, Karlsson MO. Assessment of type I error rates for the statistical sub-model in NONMEM. J Pharmacokinet Pharmacodyn 2002; 29: 251-69.
31. Hull CJ, Van Beem HBH, McLeod K, Sibbald A, Watson MJ. A pharmacodynamic model for pancuronium. Br J Anaesth 1978; 50: 1113-23.
32. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-71.
33. Rajagopalan P, Gastonguay MR. Population pharmacokinetics of ciprofloxacin in pediatric patients. J Clin Pharmacol 2003; 43: 698-710.
34. Anderson BJ, Woollard GA, Holford NH. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol 2000; 50: 125-34.
35. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-32.
36. Meibohm B, Läer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 2005; 7: E475-87.
37. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
38. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987; 34: 571-90.
39. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863-71.
40. McCoy EP, Mirakhur RK, Maddineni VR, Wierda JM, Proost JH. Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. Br J Anaesth 1996; 76: 29-33.
41. Henthorn TK, Krejcie TC, Avram MJ. Early drug distribution: a generally neglected aspect of pharmacokinetics of particular relevance to intravenously administered anesthetic agents. Clin Pharmacol Ther 2008; 84: 18-22.
42. Staals LM, de Boer HD, van Egmond J, Hope F, van de Pol F, Bom AH, Driessen JJ, Booij LH. Reversal of rocuronium-induced neuromuscular block by sugammadex is independent of renal perfusion in anesthetized cats. J Anesth 2011; 25: 241-6.
43. Abrishami A, Ho J, Wong J, Yin L, Chung F. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database Syst Rev 2009; (4): CD007362.
44. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL. 2000 CDC growth charts for the United States: methods and development. National Center for Health Statistics. Vital Health Stat 11 2002; (246): 1-190.